attention deficit/hyperactivity disorder. Disturbance of activity and attention
Conditions
Interventions
Intervention 1: methylphenudate with maximum dose of 30 mg per day and placebo for 8 weeks. Intervention 2: methylphenudate with maximum dose of 30 mg per day and risperidone with maximum dose of 1
Treatment - Drugs
methylphenudate with maximum dose of 30 mg per day and placebo for 8 weeks
methylphenudate with maximum dose of 30 mg per day and risperidone with maximum dose of 1 mg per day for 8 weeks
Sponsors
Research center for behavioral disorders and substance abuse, Hamadan University of Medical Science
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Diagnosed as ADHD according to DSM-IV TR and conner's scale; Age between 6 to12years; No other psychiatric disorders along with ADHD; No other debilitating physical illness along with ADHD; IQ>70 Exclusion Criteria: Severe drug complication during the study; abnormal labratory tests (BC,NA,K,BS,BUN,CR,TSH,AST,ALT,PRL,TOT CHOL,LDL CHOL,HDL,CHOL,TG).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement ADHD symptoms. Timepoint: first of the study and after 2nd,4th,6th and 8th week of the study. Method of measurement: Clinical Global Impression Scale and conner`s parents rating scale for ADHD. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side effects. Timepoint: after 2nd,4th,6th and 8th week of the study. Method of measurement: Clinical Global Impression Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactshahrokh akbarian
Research center for behavioral disorders and substance abuse, Hamadan University of Medical Science
Outcome results
None listed